Condition
Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
80%
4 of 5 completed with results
Key Signals
4 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (1)
P 3 (2)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00305435Phase 2CompletedPrimary
Safety Study of AMG 531 in Japanese Subjects With ITP
NCT00415532Phase 3Completed
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT01444417Phase 3Completed
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT00515203Phase 1Completed
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
NCT00454857Completed
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Showing all 5 trials